ReviewInfluence of the Gut Microbiome, Diet, and Environment on Risk of Colorectal Cancer
Section snippets
Intestinal Dysbiosis in Patients With Colorectal Cancer
The number of microbial species in human intestine is estimated to exceed 2000.13 The human intestinal microbiome primarily comprises Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria. Intestinal microbes metabolize indigestible ingredients from food, synthesize nutrients such as vitamins, detoxify metabotypes, modulate the immune response, provide signals for epithelial cell renewal and maintenance of mucosal integrity, and secrete antimicrobial products.14 Dysbiosis is defined as
Environmental Factors
The composition of microbiota is determined by genetic, environmental, and dietary factors. For example, variants in the gene encoding the vitamin D receptor affect the composition of the microbiome,76 but it is still not clear whether genetic or environmental factors have a bigger effect on the gut microbiome.77 Although there is no direct evidence, CRC-related risk factors have been associated with specific changes in the intestinal microbiota.
Mechanisms
The intestine must maintain commensal microbes and a high load of bacterial products but swiftly respond to pathogens that threaten its integrity. Analyses of gut microbiota of mice raised in germ-free or gnotobiotic conditions and transgenic mice, by using techniques such as next-generation sequencing, microbial gene mutations, and microbial RNA sequencing, have identified mechanisms by which the intestinal microbiota might contribute to or prevent the development of CRC (Figure 1). For
Screening
Alterations in the fecal microbiomes of patients with CRC have also been observed in patients with colorectal adenoma—these might be used in screening for individuals at risk for CRC. Fecal microbiome analysis identifies patients with adenomas with reasonable levels of accuracy (with area under the receiver operating curves ranging from 0.55 to 0.67 in validation studies), although this is a lower value than for detection of CRC.16,18,186, 187, 188 Combining the fecal microbiome data with
Therapy
In addition to affecting CRC development, the gut microbiota modulates the response to cancer therapy and susceptibility to toxic adverse effects, although there is only limited evidence from patients (for reviews, see Roy and Trinchieri8 and Alexander et al189). In 2013, Iida et al190 reported that alterations in the intestinal microbiota can affect the efficacy of an immunotherapy (CpG-oligonucleotide) and oxaliplatin, a platinum compound used in chemotherapy for CRC and other cancers. Both
Future Directions
Epidemiologic evidence for the effects of the gut microbiome on CRC risk comes from retrospective case-control studies of biospecimens collected from patients with established CRC or precursor lesions. It is not clear whether the identified microbial alterations are a cause or consequence of colorectal carcinogenesis.209 Moreover, clinical studies have been limited by small sample sizes (mostly <100 cases), likely underpowered to identify predictive signals from hundreds to thousands of read
References (224)
- et al.
Environmental factors, gut microbiota, and colorectal cancer prevention
Clin Gastroenterol Hepatol
(2019) - et al.
The intestinal microbiota in colorectal cancer
Cancer Cell
(2018) - et al.
Exploring gut microbes in human health and disease: pushing the envelope
Genes Dis
(2014) - et al.
Association between intraepithelial Escherichia coli and colorectal cancer
Gastroenterology
(1998) - et al.
Enhanced Escherichia coli adherence and invasion in Crohn’s disease and colon cancer
Gastroenterology
(2004) - et al.
Gut microbiota, inflammation and colorectal cancer
Genes Dis
(2016) - et al.
From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites
Cell
(2016) - et al.
Quantifying diet-induced metabolic changes of the human gut microbiome
Cell Metab
(2015) - et al.
Cancer statistics, 2019
CA Cancer J Clin
(2019) - et al.
Colorectal cancer statistics, 2017
CA Cancer J Clin
(2017)
Nutrients, foods, and colorectal cancer prevention
Gastroenterology
Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States
CA Cancer J Clin
Fusobacterium nucleatum in colorectal carcinoma tissue according to tumor location
Clin Transl Gastroenterol
International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis
Gut
Microbiota: a key orchestrator of cancer therapy
Nat Rev Cancer
The role of microbiota in the development of colorectal cancer
Int J Cancer
The gastrointestinal microbiota and colorectal cancer
Am J Physiol Gastrointest Liver Physiol
Novel insights into microbiome in colitis and colorectal cancer
Curr Opin Gastroenterol
A new genomic blueprint of the human gut microbiota
Nature
Human gut microbiome and risk for colorectal cancer
J Natl Cancer Inst
Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation
Nat Med
Leveraging existing 16S rRNA gene surveys to identify reproducible biomarkers in individuals with colorectal tumors
MBio
Gut microbiome development along the colorectal adenoma-carcinoma sequence
Nat Commun
Gut mucosal microbiome across stages of colorectal carcinogenesis
Nat Commun
Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer
Nat Med
Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma
Genome Res
Genomic analysis identifies association of Fusobacterium with colorectal carcinoma
Genome Res
Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome
Eur J Clin Microbiol Infect Dis
Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway
Int J Cancer
Association of Fusobacterium nucleatum infection with colorectal cancer in Chinese patients
World J Gastroenterol
Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis
Gut
Fusobacterium in colonic flora and molecular features of colorectal carcinoma
Cancer Res
Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy
Cell
Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer
World J Gastroenterol
Fusobacterium nucleatum and T cells in colorectal carcinoma
JAMA Oncol
Sessile serrated polyps and colon cancer prevention
Cancer Prev Res (Phila)
Distinct gut microbiome patterns associate with consensus molecular subtypes of colorectal cancer
Sci Rep
The consensus molecular subtypes of colorectal cancer
Nat Med
Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer
Science
The human gut microbiome as a screening tool for colorectal cancer
Cancer Prev Res (Phila)
Potential of fecal microbiota for early-stage detection of colorectal cancer
Mol Syst Biol
Colorectal cancer and the human gut microbiome: reproducibility with whole-genome shotgun sequencing
PLoS One
Periodontal disease, tooth loss and colorectal cancer risk: results from the Nurses’ Health Study
Int J Cancer
Fecal bacteria act as novel biomarkers for noninvasive diagnosis of colorectal cancer
Clin Cancer Res
The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients
Clin Infect Dis
Colonization with enterotoxigenic Bacteroides fragilis is associated with early-stage colorectal neoplasia
PLoS One
Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria
Science
Quantitative profiling of colorectal cancer-associated bacteria reveals associations between Fusobacterium spp., enterotoxigenic Bacteroides fragilis (ETBF) and clinicopathological features of colorectal cancer
PLoS One
A possible role of Bacteroides fragilis enterotoxin in the aetiology of colorectal cancer
Clin Microbiol Infect
Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers
ISME J
Cited by (405)
Exploring the gut microbiota and its potential as a biomarker in gliomas
2024, Biomedicine and PharmacotherapyHealthy dietary patterns, genetic risk, and gastrointestinal cancer incident risk: a large-scale prospective cohort study
2024, American Journal of Clinical Nutrition
Conflicts of interest The authors disclose no conflicts.
Funding This work was supported by the US National Institutes of Health (NIH) (grants NIDDK R01 DK105118, R01DK114126) and the UIC Cancer Center (support to Jun Sun); the American Cancer Society (grant number MRSG-17-220-01 – NEC to Mingyang Song); and NIH grants (K99 CA215314 and R00 CA215314 to Mingyang Song; K24 DK098311, R01 CA137178, R01 CA202704, R01 CA176726 to Andrew T. Chan). Andrew T. Chan is a Stuart and Suzanne Steele MGH Research Scholar.